GT Biopharma Inc
GT Biopharma Inc Stock, NASDAQ:GTBP
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product GTB-3550 is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Beverly Hills, CA.